Company Profile (AI Text)
Name: Frontier Bio
Canonical URL: https://wefunder.com/frontier.bio
Updated at: 2026-06-06T05:02:25Z

Tagline: Our Mission: End the Organ Shortage & Replace Animal Testing

Key claims:
- Total raised on Wefunder: 402656 | citation: https://wefunder.com/frontier.bio#claim-total-raised
- Total investors: 332 | citation: https://wefunder.com/frontier.bio#claim-total-investors

Verified facts:
- Total raised on Wefunder: 402656 | observed_at: 2026-06-06T05:02:25Z | expires_at: 2026-06-07T05:02:25Z
- Total investors: 332 | observed_at: 2026-06-06T05:02:25Z | expires_at: 2026-06-07T05:02:25Z

Computed metrics:
- total_amount_raised: 402656
- total_investors: 332
- team_size: 7
- featured_investor_count: 1
- faq_count: 5
- recent_post_count: 0

Quick facts:
- $5.5M in Cumulative Sales: Validated demand from customers for tissue models built with human cells. | citation: https://wefunder.com/frontier.bio#claim-fact-1
- Transforming Medicine: Reducing animal studies and advancing implantable human tissue. | citation: https://wefunder.com/frontier.bio#claim-fact-2
- Market Opportunity: Multi-billion-dollar market for human tissue models and vascular grafts | citation: https://wefunder.com/frontier.bio#claim-fact-3
- $4.1M Raised to Date: Strong investor confidence with $1.6M committed in the current round. | citation: https://wefunder.com/frontier.bio#claim-fact-4
- Patent Families: Defensible IP covering core tissue biofabrication and vascular graft technologies. | citation: https://wefunder.com/frontier.bio#claim-fact-5
- Elite Backing & Support: Funded by NSF SBIR and a Nobel Laureate, and advised by George Church. | citation: https://wefunder.com/frontier.bio#claim-fact-6
- Trusted by Industry Leaders: Clients include Mayo Clinic and Intuitive Surgical. | citation: https://wefunder.com/frontier.bio#claim-fact-7

FAQ:
- Q: I'm an interested fan, but I want to cover a few questions. 1) What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? (I acknowledge that this is far in...
  A: Thank you Jason - I will answer these one at a time. Question 1: What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? It helps to look at this from two angles: testing and clinical implantation. For testing (of therapeutics / drugs / disease modeling), we actually do not need to grow a full-sized organ. We use micro-tissues and small "organ-on-a-chip" devices (populat...
- Q: Hello, very impressive progress so far! Two questions, I wondered if you could speak to the strategy of crowdfunding as opposed to additional VC funding. I am sure some would be interested even at this early stage is why I ask. Second, any guidance on full year 2025 loss? Look...
  A: Thanks for asking about our funding strategy! Committing to the traditional venture route today often means sacrificing over a year to investor roadshows and exhausting diligence. We simply cannot afford to have our leadership sidelined for 12 months. Regulation Crowdfunding empowers us to control our capital pipeline directly, keeping our executive focus exactly where it belongs: on growing the business and executing our core mission. Beyond the time savings, choosing crowdfunding allows us ...
- Q: Hi Eric, I see that the company has been around since 2018, why is now the time to invest? What has changed in the recent years? Thank you, Glenn
  A: Thanks for the great question! We have been building our foundational technology since 2018, but the industry landscape and our own momentum have completely shifted recently. Here is why right now is the perfect time to invest: First, both the FDA and the NIH have announced major shifts away from animal testing. This is driven by the FDA Modernization Act 2.0, which explicitly authorizes alternatives. This historic legislation directly accelerates the commercial demand for our lab-grown tissu...
- Q: what kind of competition does Lung Biotechnology PBC offer for your long term prospects?
  A: Thank you for the excellent question. Lung Biotechnology PBC and their parent company United Therapeutics are doing incredible work. I'd say their most impressive work is with their xenotransplantation approach, which relies on genetically modified pig organs. While they are a pioneer in the space, we believe our autologous biofabrication approach provides the ultimate long-term solution. In fact, because they are investing so heavily in organ manufacturing, we view large players like them as...
- Q: As a critical care PA in the CTICU, I am very familiar with these patients and procedures. I love the direction of the company. For bypass surgery specifically, I know the pain points of vein harvesting, and recovery from that. It is complex physiology, but if you are able to ...
  A: Thank you for your interest! Hearing this from someone on the front lines in the CTICU is incredible validation. You know exactly why we are aiming to eliminate the painful reality of vein harvesting. With our tissue-engineered vascular graft, we hope to change the standard of care for these complex patients, and we would be honored to have someone with your clinical expertise join us as an investor.